Sivopixant (Cat No.:I036321) is a potent and selective P2X3 receptor antagonist developed for the treatment of refractory or unexplained chronic cough. By inhibiting P2X3, a receptor involved in sensory nerve activation, sivopixant suppresses the abnormal cough reflex without significantly impairing taste sensation—a common side effect of earlier P2X3 inhibitors. It has shown promising results in clinical trials, demonstrating reductions in cough frequency and improved patient tolerability. Sivopixant represents a novel, non-opioid therapeutic option for patients suffering from chronic cough unresponsive to conventional treatments.